



Supplementary Fig. 1: A, Binding of CP-870,893 to goat anti-human IgG Fc crosslinking antibody. CP-870,893 or rituximab (as a control) were pre-incubated with FITC-goat anti-human IgG Fc (XL) before addition to CD20⁺CD40⁺ Daudi cells and subsequent analysis by flow cytometry. B, Binding of CP-870,893 to goat anti-human IgG F(ab)₂ crosslinking antibody. CP-870,893 or CP-870,893 F(ab)₂ were mixed with purified human B cells before addition of FITC-goat anti-human IgG F(ab)₂ and subsequent analysis by flow cytometry. C, Binding of CP-870,893 to human CD32 on K32 cells. K32 cells were incubated with CP-870,893 or rituximab (as a positive control) and then stained with FITC goat anti-human IgG Fc (XL) to detect FcR bound antibody on the surface of these CD20^{neg}CD40^{neg} cells.